Biotest AG — Earnings Release 2007

May 3, 2007

News Details

Corporate | 3 May 2007 10:53

Biotest AG: successful start to 2007

Biotest AG / Quarter Results/Miscellaneous

Release of a Corporate News, transmitted by DGAP – a company of EquityStory

AG.

The issuer / publisher is solely responsible for the content of this announcement.

———————————————————————-

Biotest AG: successful start to 2007

– Q1 sales 12 % higher than in the same period of the previous year

– With a 16 % rise, earnings grow faster than sales

– Measures have been introduced to improve earnings situation in the

diagnostic segment

Dreieich, 3 May 2007. Financial year 2007 has started well for Biotest

Group. In the first quarter, the company, which specialises in

pharmaceuticals, biotherapeutics and diagnostics, recorded sales totaling

EUR 75.7 million, which represents a 12.1 % increase as compared with the

first three months of 2006 (EUR 67.5 million). Earnings before tax and

interest (EBIT) were up 15.9 % to EUR 8.0 million (previous year: EUR 6.9

million). In spite of a further significant rise in research and

development expenditures, earnings grew above the level of the increase in

sales.

In the first instance, growth is attributable to the continuing dynamic

upswing of business achieved by the pharmaceutical segment. In the first

quarter of 2007, Biotest recorded sales amounting to EUR 55.8 million,

which is a 17.7 % rise compared with the same period the previous year,

while sales in the diagnostic segment totaled EUR 19.9 million, which is

1.0 % lower than in the first three months of 2006.

At today’s Annual Shareholders’ Meeting in Frankfurt/Main, the Chairman of

the Management Board of Biotest AG, Professor Dr. Gregor Schulz, will give

shareholders a detailed overview of the past year’s business development

and the implementation of the Group’s strategy for growth. He will also

explain the measures introduced a few days ago to improve the earnings

situation in the diagnostic segment, which will be realized in conjunction

with a renowned management consultancy. It is the objective to transfer the

strategic business division of immunological diagnostics to an independent

entity. The aim of this is to derive the flexibility to react to any

potential options, such as the pursuit of suitable partnerships.

About Biotest

Biotest AG, Dreieich, Germany, is a company that researches and

manufactures pharmaceutical, biotherapeutic and diagnostic products and has

specialised in immunology and haematology. In its Pharmaceutical segment,

Biotest develops immunoglobulines, clotting factors and albumins based on

human blood plasma. These are used for diseases of the immune system or

haematopoietic system. In the Biotherapeutics segment, Biotest researches

into the clinical development of monoclonal antibodies, including in the

indications of rheumatoid arthritis and blood cancer. The Diagnostic

segment spans reagents and serology and microbiology systems which are

used, for example, in blood transfusions. Biotest has around 1,200

employees worldwide and its shares are listed in the Frankfurt Stock

Exchange’s Prime Standard.

Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de

Dr. Marion Wendorff, Telefon: +49 (0) 6103 801-520,

E-Mail: marion_wendorff@biotest.de

Telefax: +49 (0) 6103 801-7840

WKN, ISIN ordinary share: 522720, DE0005227201

WKN, ISIN preference share: 522723, DE0005227235

Listed: Prime Standard/official trading

Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart

DGAP 03.05.2007

———————————————————————-

Language: English

Issuer: Biotest AG

          Landsteinerstr. 5

          63303 Dreieich Deutschland

Phone: +49 – 6103 / 801 – 0

Fax: +49 – 6103 / 801 – 150

E-mail: mail@biotest.de

www: www.biotest.de

ISIN: DE0005227201, DE0005227235

WKN: 522720, 522723

Indices:

Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in

          Berlin-Bremen, Düsseldorf, Hamburg, Stuttgart

End of News DGAP News-Service

—————————————————————————